Structure via PubChem · Public domain (PubChem)
bezafibrate
Sign in to saveAlso known as Bezalip®, Cedur, Befizal, Bezafibratum, Bezafibrato, Bezafibrat, 2-(P-(2-(P-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid, Bezalip
Bezafibrate (marketed as Bezalip and various other brand names) is a fibrate drug used as a lipid-lowering agent to treat hyperlipidaemia. It helps to lower LDL cholesterol and triglyceride in the blood, and increase HDL.
Chemical data
- Formula
- C19H20ClNO4
- Molecular weight
- 361.8 g/mol
- IUPAC name
- 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid
- SMILES
- CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl
- InChIKey
- IIBYAHWJQTYFKB-UHFFFAOYSA-N
- XLogP
- 3.8
- Polar surface area
- 75.6 Ų
- H-bond donors
- 2
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- cardiovascular disease, Combined hyperlipidemia, primary biliary cirrhosis, sclerosing cholangitis
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 361.108
- Has use
- medication
Show 7 more facts
- chemical formula
- C₁₉H₂₀ClNO₄
- canonical SMILES
- CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl
- World Health Organisation international non-proprietary name
- bezafibratum
- defined daily dose
- 0.6
- subject has role
- hypolipidemic
- Commons category
- Bezafibrate
- significant drug interaction
- pravastatin
Sources (7)
via Wikidata · CC0
~4 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- Side effects
- Other uses
- Mode of action
- Synthesis
- History
- References
{{Drugbox | verifiedrevid = 443667625 | IUPAC_name = 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid | image = Bezafibrate.svg | image_class = skin-invert-image
| tradename = | Drugs.com = | MedlinePlus = a682711 | pregnancy_category = | legal_UK = POM | legal_US = Rx-only | routes_of_administration = Oral
Excerpted from Wikipedia’s “bezafibrate” article, available under the CC BY-SA 4.0 licence.